Skip to main content

Kintz Samuel's Form 4/A amendment

Amended

Enliven Therapeutics, Inc.ELVN · filed Aug 21, 2025

Accession no.
0001415889-25-022649
Filed
Aug 21, 2025
Trade date
Aug 20, 2025
Filing delay
1 day
Rule 10b5-1 plan
Checked
Original filed
Aug 20, 2025

This filing lists 1 non-derivative transaction. It carries over 2 transactions from the original filing that it did not restate. Open-market sales total $250.2K. It was filed 1 day after the trade.

This amendment restates part of 0001415889-25-022459 (filed Aug 20, 2025). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kintz SamuelCIK 0001967168Director, Officer (PRESIDENT AND CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 20, 2025Common StockSSaleDisposed−1,517$20.00F3−$30,340927,892Indirect

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001415889-25-022459 (filed Aug 20, 2025).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001415889-25-022459
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 18, 2025Common StockSSaleDisposed−10,393$20.02F2−$208,067.86929,999Indirect
Aug 19, 2025Common StockSSaleDisposed−590$20.00−$11,800929,409Indirect

Footnotes on the original

The footnotes that the prices of these transactions refer to on the original filing.

F2

This transaction was executed in multiple trades at prices ranging from $19.75 to $20.715. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The original Form 4, filed August 20, 2025, did not reflect the stock sale on August 20, 2025.

F2

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F3

This transaction was executed in multiple trades at prices ranging from $20.00 to $20.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F4

The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

Read the full filing on SEC EDGAR (opens in a new tab)